PASG vs. XBIT, TLSA, ORMP, OPTN, COYA, CLYM, ZNTL, CCCC, PLRX, and VOR
Should you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include XBiotech (XBIT), Tiziana Life Sciences (TLSA), Oramed Pharmaceuticals (ORMP), OptiNose (OPTN), Coya Therapeutics (COYA), Climb Bio (CLYM), Zentalis Pharmaceuticals (ZNTL), C4 Therapeutics (CCCC), Pliant Therapeutics (PLRX), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry.
Passage Bio vs.
Passage Bio (NASDAQ:PASG) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
Passage Bio presently has a consensus target price of $7.50, indicating a potential upside of 2,172.73%. Given Passage Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Passage Bio is more favorable than XBiotech.
XBiotech received 264 more outperform votes than Passage Bio when rated by MarketBeat users. Likewise, 69.98% of users gave XBiotech an outperform vote while only 68.83% of users gave Passage Bio an outperform vote.
Passage Bio has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.
In the previous week, Passage Bio had 4 more articles in the media than XBiotech. MarketBeat recorded 4 mentions for Passage Bio and 0 mentions for XBiotech. XBiotech's average media sentiment score of 0.00 beat Passage Bio's score of -0.02 indicating that XBiotech is being referred to more favorably in the news media.
XBiotech's return on equity of -15.99% beat Passage Bio's return on equity.
XBiotech has higher revenue and earnings than Passage Bio. XBiotech is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.
53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 4.3% of Passage Bio shares are owned by insiders. Comparatively, 33.1% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
XBiotech beats Passage Bio on 9 of the 16 factors compared between the two stocks.
Get Passage Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Passage Bio Competitors List
Related Companies and Tools
This page (NASDAQ:PASG) was last updated on 4/20/2025 by MarketBeat.com Staff
Buy PASG Stock Free PASG Stock Alerts